A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Clinical Trials Related to T-DM1
Related studies linked through entity extraction aliases.
A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy
- Status
- RECRUITING
- Phase
- PHASE3
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE3
Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of HER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 Alone
- Status
- UNKNOWN
- Phase
- PHASE2
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE1
T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Study Of Pembrolizumab In Combination With Trastuzumab-DM1
- Status
- COMPLETED
- Phase
- PHASE1
An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2